Compare GSK Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SUVEN LIFESCIENCES - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SUVEN LIFESCIENCES GSK PHARMA/
SUVEN LIFESCIENCES
 
P/E (TTM) x 52.5 19.7 267.4% View Chart
P/BV x 11.1 4.0 277.6% View Chart
Dividend Yield % 1.4 0.5 270.5%  

Financials

 GSK PHARMA   SUVEN LIFESCIENCES
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
SUVEN LIFESCIENCES
Mar-19
GSK PHARMA/
SUVEN LIFESCIENCES
5-Yr Chart
Click to enlarge
High Rs3,595338 1,064.6%   
Low Rs1,253169 739.7%   
Sales per share (Unadj.) Rs184.752.1 354.2%  
Earnings per share (Unadj.) Rs26.36.8 384.9%  
Cash flow per share (Unadj.) Rs29.28.6 340.3%  
Dividends per share (Unadj.) Rs20.001.50 1,333.3%  
Dividend yield (eoy) %0.80.6 139.5%  
Book value per share (Unadj.) Rs126.365.3 193.5%  
Shares outstanding (eoy) m169.40127.28 133.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.14.9 269.9%   
Avg P/E ratio x92.237.1 248.4%  
P/CF ratio (eoy) x83.129.6 281.0%  
Price / Book Value ratio x19.23.9 494.1%  
Dividend payout %76.122.0 346.4%   
Avg Mkt Cap Rs m410,62632,272 1,272.4%   
No. of employees `0005.01.1 458.4%   
Total wages/salary Rs m5,372661 812.5%   
Avg. sales/employee Rs Th6,306.76,132.2 102.8%   
Avg. wages/employee Rs Th1,083.1611.1 177.2%   
Avg. net profit/employee Rs Th898.0803.5 111.8%   
INCOME DATA
Net Sales Rs m31,2816,635 471.5%  
Other income Rs m1,023242 422.3%   
Total revenues Rs m32,3046,877 469.7%   
Gross profit Rs m6,0091,604 374.6%  
Depreciation Rs m486221 219.5%   
Interest Rs m638 15.9%   
Profit before tax Rs m6,5401,587 412.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2870-   
Tax Rs m2,373718 330.5%   
Profit after tax Rs m4,454869 512.3%  
Gross profit margin %19.224.2 79.4%  
Effective tax rate %36.345.2 80.2%   
Net profit margin %14.213.1 108.7%  
BALANCE SHEET DATA
Current assets Rs m20,0616,232 321.9%   
Current liabilities Rs m14,5431,490 976.0%   
Net working cap to sales %17.671.5 24.7%  
Current ratio x1.44.2 33.0%  
Inventory Days Days5786 65.7%  
Debtors Days Days1483 17.0%  
Net fixed assets Rs m14,3434,043 354.7%   
Share capital Rs m1,694127 1,330.7%   
"Free" reserves Rs m19,7048,183 240.8%   
Net worth Rs m21,3988,310 257.5%   
Long term debt Rs m218 11.2%   
Total assets Rs m39,11310,389 376.5%  
Interest coverage x1,091.043.1 2,531.0%   
Debt to equity ratio x00 4.4%  
Sales to assets ratio x0.80.6 125.2%   
Return on assets %11.48.7 130.6%  
Return on equity %20.810.5 198.9%  
Return on capital %31.919.5 163.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5345,622 9.5%   
Fx outflow Rs m7,0911,799 394.1%   
Net fx Rs m-6,5573,822 -171.5%   
CASH FLOW
From Operations Rs m3,994356 1,123.4%  
From Investments Rs m-1,433-279 514.5%  
From Financial Activity Rs m-3,584-225 1,592.0%  
Net Cashflow Rs m-1,023-148 690.4%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.0 -  
FIIs % 23.8 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 36.5 42.2%  
Shareholders   102,036 37,287 273.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   J.B.CHEMICALS  VENUS REMEDIES  STERLING BIOTECH  CADILA HEALTHCARE  AUROBINDO PHARMA  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 19, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE GSK PHARMA WITH

MARKET STATS